1 showed that a ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) of 38 or lower ruled out preeclampsia with a negative predictive value of 99.3% within 1 week in women with clinical suspicion of it. Critical in this study are the inclusion criteria used to define "impending" preeclampsia. In medicine, a definition of suspected preeclampsia is lacking, and the inclusion of patients at low risk may artificially increase the negative predictive value of a test by diluting the weight of false negative events. Only 41.5% of the women in the validation cohort had new-onset hypertension or an exacerbation of preexisting hypertension. Other clinical symptoms considered as inclusion criteria are often described in women with overt preeclampsia and used to define its severity, but in the absence of an elevated blood pressure, they lose their clinical importance. We wonder whether the simple inclusion of blood pressure instead of the angiogenic ratio in the evaluation of symptomatic patients would have yielded the same figure for the negative predictive value.
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The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia
To the Editor: The article by Zeisler and colleagues (Jan. 7 issue) 1 showed that a ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) of 38 or lower ruled out preeclampsia with a negative predictive value of 99.3% within 1 week in women with clinical suspicion of it. Critical in this study are the inclusion criteria used to define "impending" preeclampsia. In medicine, a definition of suspected preeclampsia is lacking, and the inclusion of patients at low risk may artificially increase the negative predictive value of a test by diluting the weight of false negative events. Only 41.5% of the women in the validation cohort had new-onset hypertension or an exacerbation of preexisting hypertension. Other clinical symptoms considered as inclusion criteria are often described in women with overt preeclampsia and used to define its severity, but in the absence of an elevated blood pressure, they lose their clinical importance. We wonder whether the simple inclusion of blood pressure instead of the angiogenic ratio in the evaluation of symptomatic patients would have yielded the same figure for the negative predictive value. No potential conflict of interest relevant to this letter was reported. 
DOI: 10.1056/NEJMc1602338
The authors reply: In PROGNOSIS (Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia Study), pregnant women were enrolled on the basis of signs and symptoms of preeclampsia or the HELLP syndrome (characterized by hemolysis, elevated liver-enzyme levels, and low platelet counts), including high blood pressure, as described in clinical guidelines.
1,2
The prevalence of preeclampsia in our cohort was 19.0%, as compared with 2 to 5% among all pregnant women (indicating that women with a high risk of preeclampsia were included in the study). Blood pressure is limited in predicting adverse pregnancy outcomes (e.g., the HELLP syndrome and eclampsia). 3 Importantly, up to 20% of cases of the HELLP syndrome develop in women without previous onset of hypertension. data set. As we noted in the article, a post hoc analysis suggested that the addition of the sFlt-1:PlGF ratio to blood-pressure and proteinuria assessments improved the prediction of preeclampsia over these other measures alone. Since publication of their article, the authors report no further potential conflict of interest. 3 Such infections are also common in women, although with additional testing for rectal and oropharyngeal infection, the increment is less. 4 Many anecdotal reports have indicated that azithromycin is less effective than doxycycline for the treatment of rectal, oropharyngeal, or genital infection. For example, in a retrospective cohort study, 23 of 136 men (17%) tested positive for chlamydia infection 14 to 60 days after treatment with azithromycin, and 0 of 36 men tested positive 14 to 60 days after treatment with doxycycline. 5 These studies were suggestive, not conclusive. The biologic features of C. trachomatis infection and antibiotic levels may vary according to the anatomical site of infection. Data from trials of treatment of extragenital C. trachomatis infection as well as from trials of treatment of genital C. trachomatis infection are lacking. Julius Schachter, Ph.D.
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